Articles tagged with Drug Development
Researchers found significant functional variations between rodent and human PD-1 due to evolutionary divergence. The study reveals a unique motif present in most mammals but missing in rodents, leading to uniquely weaker rodent PD-1.
Researchers at Rice University have created a sustainable way to integrate chlorine into chemical building blocks, reducing costs and environmental impact. The new process uses iron and sulfur catalysts activated by mild blue light, eliminating harsh chemicals and high temperatures.
Researchers found that bumetanide treatment normalizes neonatal social communication in newborn pups with the fragile X mutation, but reduces post-pubertal social interaction. The study suggests stage-specific effects on social development and raises questions about timing and dosing of bumetanide for targeted interventions.
Researchers have unveiled a critical mechanism linking cellular stress in the brain to Alzheimer's disease progression, highlighting microglia as central players in both protective and harmful responses. The study reveals that blocking a specific stress pathway reverses symptoms of Alzheimer's disease in preclinical models.
A new study published in Neurology suggests that the recently approved drug atogepant can start working to prevent migraines as early as the first day of treatment. The study, which focused on three trials over 12 weeks, found significant reductions in migraine frequency and severity among participants taking the drug.
A UC Riverside-led team, funded by the NIH, aims to uncover molecular factors governing gene regulation and chromatin organization in P. falciparum. The project focuses on long non-coding RNAs, which play a crucial role in regulating gene expression and influencing disease progression.
Researchers create SciAgents framework to autonomously generate and evaluate promising research hypotheses in biologically inspired materials. The framework uses graph reasoning methods to organize relationships between scientific concepts, mimicking biological systems.
Nearly 50 ISS National Lab-sponsored payloads splashed down safely on SpaceX’s CRS-31 mission, including research for early cancer detection and neurodegenerative conditions treatments. The investigations leveraged the space station's unique environment to improve life on Earth.
A phase 1/2 clinical trial has demonstrated the safety and effectiveness of the AEF0217 molecule in improving cognitive function in people with Down syndrome. Measured outcomes showed significant improvements in behavioral skills, social interactions, and cognitive flexibility.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
A novel radiotracer has accurately identified a crucial cancer biomarker, Trop2, found in various types of cancer. The radiotracer, <sup>18</sup> F-AlF-RESCA-T4, enables precise visualization of Trop2 expression and can differentiate lung inflammation from cancer.
Researchers at MIT have developed Boltz-1, an open-source AI model that achieves state-of-the-art performance in predicting biomolecular structures. The model surpasses AlphaFold3, which is limited to academic research and commercial use, by incorporating new algorithms and improving prediction efficiency.
A team of University of Melbourne researchers has developed a novel drug delivery system composed of metal-biomolecule networks (MBNs), which eliminate the need for toxic drug carriers. The MBNs show antiviral, antibacterial, antifungal, anti-inflammatory and anti-cancer properties, potentially increasing success in drug development.
Researchers at UW-Madison found two microbial bile acids that affect colon cancer risk in opposite ways, with one slowing growth and the other fueling tumors. The study provides a roadmap for new cancer detection methods and treatments.
Researchers investigate how perturbed gene expression contributes to neurodegenerative disorders like Alzheimer's. Alternative polyadenylation, a mechanism regulating protein production, is being studied for its potential role in the disease.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
A team of researchers has identified an 18-digit code within a protein called Wnt7a that allows it to attach itself to exosomes, enabling targeted delivery of proteins throughout the body. This discovery has major implications for the development of new therapies for diseases such as Duchenne muscular dystrophy.
A new review published in Blood Cancer Discovery outlines how research supported a recent FDA committee decision to allow minimal residual disease as an endpoint for accelerated approval in multiple myeloma. This decision could cut a decade off the drug development process, enabling faster innovation in cancer treatment.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
Scientists identify hederagenin, a highly selective antagonist of NPFFR1, to block chronic pain. The discovery could facilitate the rational design of future therapeutics for pain management.
Researchers identified the critical role of TIMM50 protein in mitochondrial energy production and its link to a severe and rare neurological disease. The study's findings suggest potential targets for future drug treatments and advance research on protein import into mitochondria in brain cells.
Researchers developed a deep-learning model to predict organoid development at an early stage, outperforming human experts in accuracy and speed. The model classifies bright-field images of organoids into three quality categories, indicating their potential for regenerative medicine applications.
Researchers at Tokyo University of Science have developed a new, highly selective and efficient method for synthesizing anti-cancer compounds. The innovative approach uses isopropyl magnesium bromide as a base to improve selectivity and scalability.
A new Simon Fraser University study finds that antidepressants are associated with reduced genital sensitivity in 13% of users, compared to 1% of other psychiatric medication users. The study highlights the need for better patient education and warnings about potential side effects.
A new study has solved a years-old mystery about which patients with aggressive breast cancer are helped by a targeted cancer treatment. The researchers found that low levels of the protein IGFBP7 can predict which patients will benefit from the treatment, providing hope for its continued development.
Chronic fatigue syndrome patients' immune T cells become exhausted, a condition well-studied in cancer. Researchers now explore potential treatments to reverse this state, which may benefit ME/CFS patients.
The study found that lemongrass powder significantly increased the fiber and mineral content of wheat flour-based biscuits. The powder's phytochemical extracts also boosted the biscuits' antioxidant activity. Optimal levels of lemongrass powder were determined to be 2.5% for taste, flavor, and overall acceptability.
Researchers developed a platform to produce mature, uniform organoids using a three-dimensional engineered membrane. This breakthrough enables consistent quality and improved efficiency for practical applications in clinical trials and drug development.
A team of researchers developed a new technique combining methods to simulate molecules, achieving accuracy and efficiency on the Frontier exascale supercomputer. They broke records with simulations of over one million electrons and scaled their algorithm to an EFlop/s processing quintillion calculations per second.
Researchers at Tokyo University of Science have developed a novel co-culture system that facilitates cultivating multiple indigenous skin bacteria in a balanced state. This breakthrough allows for detailed analysis of the biology of indigenous skin bacteria, which can lead to new treatments for skin diseases and improved quality of life.
Researchers found that genetic collisions between transcription and DNA replication lead to large tandem duplications in cancer cells, which can be identified through dosage imbalance. These duplicates are associated with poor patient survival and high correlation with mutations in genes TP53, CDK12, and SPOP.
EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating detectable virus within 24 hours. It also recruits naturally occurring antibodies to fight the virus, reducing viral loads and protecting against lung damage.
A new finger prick test for Alzheimer's disease has shown strong performance in a European study, measuring biomarkers in blood from superficial vessels. The test could soon be implemented globally, increasing accessibility to Alzheimer's testing without the need for high-sensitivity analyses.
A new study from Uganda documents partial resistance to artemisinin in 11 out of 100 African children with severe malaria, suggesting a growing concern for the efficacy of lifesaving malaria treatments. The study also reveals that 10 patients who were thought to have been cured suffered repeat malaria attacks within 28 days.
Researchers at New York University developed a mathematical approach, Crystal Math, to predict molecular crystal structures in hours, bypassing weeks or months of supercomputer processing. This breakthrough could speed up R&D for drugs and electronic devices.
A WVU research partnership with the DEA aims to improve fast and accurate identification of psychoactive substances like fentanyl. The Expert Algorithm for Substance Identification (EASI) will enable labs using different instruments to share data on chemical profiles, helping to identify drugs like fentanyl.
A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.
Researchers discovered that NMDA receptors set the baseline level for neural network activity, helping maintain stable brain function. The study's findings suggest potential innovative treatments for diseases linked to disrupted neural stability.
Researchers have developed a simple model system to break down fibrils into their constituent single units or liquid droplets. This discovery has the potential to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by targeting pathological fibrils.
The C-Path initiative aims to generate drug development solutions that reflect each person's unique experience, leveraging diverse data and innovative technologies like AI and digital health. GEM-PD seeks to address unmet need in Parkinson's disease therapies by focusing on sex and gender differences.
A groundbreaking metagenomic sequencing test has proven effective in rapidly diagnosing almost any kind of pathogen, including viruses, bacteria, fungus or parasite. The test analyzes all nucleic acids present in a sample, replacing multiple tests with a single one and speeding up diagnosis.
Scientists are exploring the use of fluralaner, an insecticide used to treat pets, as a larvicide against mosquitoes and flies. The study found that fluralaner is effective in controlling mosquito larvae for five weeks and midge larvae for eight weeks.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
A team of scientists at IISc has devised a way to break down biofilm barriers using an enzyme from the cow’s digestive tract, making bacteria more susceptible to antibiotics. The enzyme successfully broke down biofilms in four strains of Klebsiella pneumoniae and prevented its development altogether.
A new PACT system offers rapid imaging of living organisms, enabling the tracking of whole-body dynamics and disease progression. The system achieves spatial resolution of approximately 212 micrometers and enables the visualization of oxygen saturation across complex biological systems.
Junior Professor Johannes Walker at the University of Göttingen has been awarded an Exploration Grant to develop new strategies for synthesizing saturated polycyclic molecules, potentially leading to new medicines. The award will enable his team to explore new lines of research and contribute to the development of new drugs.
Critical Path Institute (C-Path) has announced key leadership appointments: Dr. Diane Stephenson promoted to Vice President of Neurology and Nadine Tatton welcomed as new Executive Director of CPAD Consortium. This move aims to advance neurodegenerative disease research, including Alzheimer's and Parkinson's diseases.
Researchers found higher levels of CD47 expression linked to more aggressive tumors, immune cells, and oncogenic signaling. Targeting CD47 could lead to improved outcomes with immunotherapy drugs, especially in cases where existing treatments are ineffective.
Researchers at Memorial Sloan Kettering Cancer Center have identified a potential therapeutic approach to treat RAS-driven cancers using artificial intelligence. Additionally, they developed a new model for investigating lung cancer metastasis and uncovered how changes to helper proteins drive cancer cell survival.
The partnership aims to simplify cooperation in ATMPs and related technologies, promoting research and development within academia, healthcare, and industry. The collaboration will explore opportunities for project and business development, quality-controlled production, and clinical trials.
The SpaceX CRS-31 mission to the International Space Station includes studies on in-space manufacturing, cardiac health, and a method for repairing spacecraft damaged by debris. Multiple payloads sponsored by the ISS National Laboratory are bound for the orbiting outpost.
Researchers have developed a large-scale drug screening technique that tracks drug targets inside cells, allowing for the identification of potential new drugs. The technology screens candidate drugs 100 times faster than standard manual techniques, enabling the discovery of previously unknown drugs.
A new anti-cancer agent has been developed that targets glutathione in cancer cells, switching it off and causing tumor shrinkage. The catalyst-based therapy accumulates specifically in tumor tissue, showing promising results in animal studies and potential for further human trials.
A recent study revealed that nanoplastic particles impair antibiotic effects and promote bacterial resistance. The research team found that plastics like nylon bind strongly to antibiotics, increasing the risk of resistance.
A team of researchers at the University of Toronto has developed a rapid screening system to identify compounds that can stop the growth of amyloid proteins. The study found 40 compounds that demonstrate the ability to inhibit amyloid formation, providing a promising lead for future disease treatments.
A new study has found that rifaximin, an antibiotic commonly prescribed for liver disease patients, is driving the emergence of a deadly superbug. The antibiotic triggers specific changes in bacteria that make them resistant to last-resort antibiotics like daptomycin.
The Colorectal Cancer Alliance's Project Cure CRC has awarded nearly $5 million in research grants to advance urgent science in colorectal cancer. Recent awardees are working on topics such as radioimmunotherapy, CRISPR technology, and the protein drug ProAgio to better understand and treat this disease.
The novel coronavirus SARS-CoV-2 has an enzyme that counteracts the innate defense mechanism against viruses, allowing it to evade the innate immune system and become more infectious. Understanding this mechanism may lead to the development of new antiviral drugs and treatments.
Researchers demonstrate the first cross-chiral exponential amplification of an RNA enzyme, potentially leading to the development of cross-chiral therapeutics and biotechnologies. The discovery suggests that a bioengineer can create a new form of biochemical evolution by using both left- and right-handed molecules.
Scientists have identified a key driver of brain inflammation in neurological diseases, proposing a new treatment approach by neutralizing fibrin. This protein, involved in blood coagulation, triggers neurologic diseases by hijacking the immune system, resulting in damaged neurons.